Q2
BMRN — Q2 2026 Financial Report Analysis
BioMarin's revenue rose 19.9% to $989.7M as the Amicus acquisition added GALAFOLD and POMBILITI and VOXZOGO grew 14%, but deal costs, amortization and new debt cut GAAP EPS 81% to $0.23; 2026 guidance was raised.